Vascular Therapies Stock
Vascular Therapies is a biopharma company that aims to improve vascular surgery outcomes in patients with kidney and vascular diseases.
Sign up today and learn more about Vascular Therapies Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Vascular Therapies Stock
Vascular Therapies (VT) is a biopharmaceutical company committed to the development and commercialization of innovative new treatments to address major unmet clinical needs of patients requiring a vascular access to support hemodialysis. Our lead product candidate, containing sirolimus, has received orphan drug designations in the U.S. and E.U. for the dialysis vascular access indications. The company was founded in 2001 and headquartered in Cresskill, New Jersey.
Funding History
| April 2011 | $646K |
|---|---|
| June 2011 | $3.2M |
| July 2013 | $5.2M |
| February 2015 | $16.2M |
| October 2018 | $12.4M |
| November 2019 | $7.4M |
| January 2020 | $17.3M |
| August 2021 | $3.7M |
| March 2022 | $24.0M |
Management
Founder, Chief Scientific Officer & Board Member
Sriram Iyer
CEO
John McDermott
Press
prnewswire - Aug, 29 2022
Vascular Therapies Initiates Enrollment in ACCESS 2 Clinical Trialprnewswire - Mar, 30 2022
Vascular Therapies Completes $25 Million Private Financingmassdevice - Jan, 30 2020
Vascular Therapies closes $17.3m financingprnewswire - Nov, 13 2017
Vascular Therapies Announces Preliminary Results from its Phase 3 AV Fistula StudyEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
